[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100352063":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":10,"locations":20,"responsibleParty":26,"collaborators":10,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":34,"eligibilityCriteria":35,"healthyVolunteers":30,"sex":36,"minAge":37,"maxAge":10,"enrollmentInfo":38,"targetDuration":10,"studyType":41,"phases":10,"briefSummary":42,"conditions":43,"keywords":45,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"Bayer","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with PAH",null,"Adult male and female patients from Argentina diagnosed with pulmonary arterial hypertension (PAH) of WHO functional class I between 01-Jan-2012 and 31-Dec-2017 and with at least one year of follow-up.",[13],"Drug: PAH medication",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","PAH medication","Any PAH-targeted medication",[9],[21],{"facility":22,"status":10,"city":23,"state":10,"zip":10,"country":24,"countryCode":25,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Many facilities","Multiple Locations","Argentina","AR",{"type":27,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100352063","study-performed-at-various-medical-centers-to-learn-more-about-survival-and-expected-course-of-pulmonary-arterial-hypertension-a-type-of-high-blood-pressure-in-the-lungs-related-to-the-narrowing-of-the-small-blood-vessels-in-the-lungs-100352063",false,"NCT03863990","Study Performed at Various Medical Centers to Learn More About Survival and Expected Course of Pulmonary Arterial Hypertension, a Type of High Blood Pressure in the Lungs Related to the Narrowing of the Small Blood Vessels in the Lungs","Survival and Prognostic Factors in Pulmonary Arterial Hypertension. A Multicenter Observational Registry (START)","START","Inclusion Criteria:\n\n* Consecutive newly diagnosed patients by Right heart catheterization (RHC) from 01-Jan-2012 to 31-Dec-2017, belonging to one of the following of Group 1 PAH subgroups: Idiopathic (IPAH), or Heritable (HPAH), or Drug or toxin induced, or Associated (APAH) with one of the following: Connective tissue disease; Congenital heart disease with simple systemic to pulmonary shunt at least 1 year after surgical repair; Portal Hypertension or HIV infection.\n* Diagnosis of PAH by RHC exhibiting a mean pulmonary artery pressure (MPAP) ≥ 25 mmHg and a pulmonary artery wedge pressure (PAWP) ≤15 mmHg at normal or reduced cardiac output, according to European Society of Cardiology and European Respiratory Society (ESC\u002FERS) 2009 guidelines or MPAP ≥ 25 mmHg and a PAWP ≤15 mmHg and a pulmonary vascular resistance (PVR) \\> 3 WU according to ESC\u002FERS 2015 guidelines.\n* Patients with at least one year documented follow up or that have died or received transplant before 1 year of follow up after baseline RHC and that have initiated treatment with a PAH-targeted medication.\n\nExclusion Criteria:\n\n* Patients with severe concomitant left heart disease (left ventricular ejection fraction \\\u003C35%).\n* Patients with restrictive lung disease (Forced vital capacity (FVC) \\\u003C60% predicted) other than connective tissue disease or obstructive lung disease (forced expiratory volume (FEV) \\\u003C60% predicted, with FEV1\u002FFVC\\\u003C70%).\n* Clinical or radiological evidence of Pulmo-Veno-Occlusive Disease (PVOD) or Pulmonary Capillary Haemangiomatosis (PCH).\n* Hypertrophic obstructive cardiomyopathy.\n* Severe proven or suspected coronary artery disease.\n* Congenital or acquired valvular or myocardial disease if clinically significant apart from tricuspid valvular insufficiency due to pulmonary hypertension.\n* Underlying medical disorders at baseline with an anticipated life expectancy below 2 years (e.g. active cancer disease with localized and\u002For metastasized tumor mass) or Clinical relevant hepatic dysfunction (Child-Pugh B and C) or Renal insufficiency (glomerular filtration rate \\\u003C30 mL\u002Fmin).\n* Diagnosis of a pulmonary hypertension from WHO groups 2, 3, 4 or 5.","ALL","18 Years",{"count":39,"type":40},104,"ACTUAL","OBSERVATIONAL","In this study researchers want to learn more about Pulmonary Arterial Hypertension, a type of high blood pressure in the lungs related to the narrowing of the small blood vessels in the lungs (group 1 according to WHO classification). Goal of the study is to describe the signs and risk factors of the illness at study start and the chances of survival.",[44],"Pulmonary Arterial Hypertension",[46,47,48,49],"PAH prognosis","PAH outcomes","PAH survival","PAH risk status","COMPLETED","2021-04-29",{"date":53,"type":40},"2021-05-04",{"date":55,"type":40},"2019-07-15",{"date":57,"type":40},"2020-05-11",{"name":5,"class":6},1]